Results 21 to 30 of about 19,369 (169)

A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma

BMC Cancer, 2023
Background There are no standard third-line treatment options for metastatic pancreatic ductal adenocarcinoma (mPDAC). Trametinib in combination with hydroxychloroquine (HCQ) or CDK4/6 inhibitors for pancreatic adenocarcinoma showed promising efficacy in
Hui Tang, Yuping Ge, Tingting You, Xiaoyuan Li, Yingyi Wang, Yuejuan Cheng, Chunmei Bai   +6 more
doaj   +1 more source

Efficacy and Safety of Trametinib in Neurofibromatosis Type 1-Associated Plexiform Neurofibroma and Low-Grade Glioma: A Systematic Review and Meta-Analysis

Pharmaceuticals, 2022
Trametinib has been used in neurofibromatosis type 1 (NF1) patients, especially those with unresectable nerve tumors, but no systematic review based on the latest studies has been published.
Dun Wang, Lingling Ge, Zizhen Guo, Yuehua Li, Beiyao Zhu, Wei Wang, Chengjiang Wei, Qingfeng Li, Zhichao Wang   +8 more
doaj   +1 more source

Combined VEGFR and MAPK pathway inhibition in angiosarcoma

Scientific Reports, 2021
Angiosarcoma is an aggressive malignancy of endothelial cells that carries a high mortality rate. Cytotoxic chemotherapy can elicit clinical responses, but the duration of response is limited.
Michael J. Wagner, Yasmin A. Lyons, Jean H. Siedel, Robert Dood, Archana S. Nagaraja, Monika Haemmerle, Lingegowda S. Mangala, Pritha Chanana, Alexander J. Lazar, Wei-Lien Wang, Vinod Ravi, Eric C. Holland, Anil K. Sood   +12 more
doaj   +1 more source

Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer

Cancer Treatment and Research Communications, 2022
: OBJECTIVE: This phase I trial (NCT01912625) evaluated the safety and pharmacokinetics of definitive concurrent chemoradiotherapy (cCRT) and the radiosensitizer trametinib (MEK1/2 inhibitor) for KRAS-mutated nonmetastatic non-small cell lung cancer ...
Steven H Lin, Heather Y Lin, Vivek Verma, Meng Xu-Welliver, Peter F Thall, Luyang Yao, Peter Y Kim, Dan S Gombos, Jitesh D Kawedia, Ritsuko Komaki, Daniel R Gomez, Quynh-Nhu Nguyen, Michael S O'Reilly, Charles Lu, Frank V Fossella, Ferdinandos Skoulidis, Jianjun Zhang, Anne S Tsao, John V Heymach, George R Blumenschein   +19 more
doaj   +1 more source

Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines.

PLoS ONE, 2014
Cellular signaling pathways involving mTOR, PI3K and ERK have dominated recent studies of breast cancer biology, and inhibitors of these pathways have formed a focus of numerous clinical trials.
Euphemia Y Leung, Ji Eun Kim, Marjan Askarian-Amiri, Gordon W Rewcastle, Graeme J Finlay, Bruce C Baguley   +5 more
doaj   +1 more source

The MEK Inhibitor Trametinib Improves Outcomes following Subarachnoid Haemorrhage in Female Rats

Pharmaceuticals, 2022
Aneurysmal subarachnoid haemorrhage (SAH) is a haemorrhagic stroke that causes approximately 5% of all stroke incidents. We have been working on a treatment strategy that targets changes in cerebrovascular contractile receptors, by blocking the MEK/ERK1 ...
Jesper Peter Bömers, Anne-Sofie Grell, Lars Edvinsson, Sara Ellinor Johansson, Kristian Agmund Haanes   +4 more
doaj   +1 more source

Sporadic Metastatic Malignant Peripheral Nerve Sheath Tumour with an NF1 Mutation Responding to Trametinib: A Case Report

Case Reports in Oncology, 2023
Sporadically occurring malignant peripheral nerve sheath tumours (MPNSTs) can have a variety of genomic alterations including altered NF1, leading to activation of the RAS-RAF-MEK-ERK signalling pathway. Trametinib is an inhibitor of MEK1 and MEK2.
Nadia Hitchen, Matthew Cross, George Laking, Joanna Connor, Clement Korenbaum   +4 more
doaj   +1 more source

CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma

Scientific Reports
Pancreatic ductal adenocarcinoma (PDAC) is not sensitive to most chemotherapy drugs, leading to poor chemotherapy efficacy. Recently, Trametinib and Palbociclib have promising prospects in the treatment of pancreatic cancer.
Ke Cheng, Zijian Zhou, Qiangxing Chen, Zixin Chen, Yu Cai, He Cai, Shangdi Wu, Pan Gao, Yunqiang Cai, Jin Zhou, Xin Wang, Zhong Wu, Bing Peng   +12 more
doaj   +1 more source

Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment

Molecular Oncology, 2022
A more comprehensive understanding of how cells respond to drug intervention, the likely immediate signalling responses and how resistance may develop within different microenvironments will help inform treatment regimes.
John C. Dawson, Alison Munro, Kenneth Macleod, Morwenna Muir, Paul Timpson, Robert J. Williams, Margaret Frame, Valerie G. Brunton, Neil O. Carragher   +8 more
doaj   +1 more source

Rapid Response to Trametinib Combined With Chemotherapy for Infant BRAF‐Fused Chiasmatic Glioma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Infants, less than 1 year, with chiasmatic gliomas (ICG) present a major therapeutic challenge due to large tumor size, decreased vision, rapid progression, and poor response to vincristine/carboplatin chemotherapy. The majority have a BRAF fusion, which may respond to downstream MEK inhibitors but response time is slow. There are no safety or
Helen Toledano, Alexander Yelak, Walid Kaadan, Shlomo Caduri, Rivka Friedland, Orli Michaeli, Gad Dotan, Osnat Konen   +7 more
wiley   +1 more source